Quantumzyme Corp. (OTC: QTZM), a biotransformation company based in San Diego, California, today announced a significant advancement in its proprietary enzyme development platform. The new generation of high-performance enzymes is designed to improve efficiency across pharmaceutical manufacturing processes, particularly in the production of active pharmaceutical ingredients (APIs) and complex chiral compounds.
The newly developed enzymes demonstrate enhanced stability, selectivity, and compatibility with lower-cost extraction solvents such as isopropyl alcohol, offering an alternative to commonly used solvents like ethyl acetate. According to internal testing and early-stage evaluations, these characteristics could enable pharmaceutical manufacturers to reduce solvent usage, raw material costs, and downstream processing requirements while maintaining high product quality.
Preliminary internal analyses suggest that under certain manufacturing conditions, Quantumzyme's next-generation enzyme systems could support meaningful improvements in production economics. Potential benefits include reduced solvent and material costs, improved reaction efficiency and conversion rates, lower energy and purification requirements, shorter production cycles, and enhanced scalability for commercial manufacturing.
“These results mark an important step forward in our efforts to modernize pharmaceutical manufacturing through advanced enzyme engineering,” stated Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp. “Our platform is designed to help manufacturers improve process efficiency and cost structure while supporting broader sustainability objectives. While results will vary by application, we believe this technology has the potential to deliver significant value across a range of pharmaceutical processes.”
The technology is particularly relevant for high-volume APIs and complex chiral compounds, where solvent usage and purification steps account for a substantial portion of total manufacturing costs. Quantumzyme's platform is designed for integration into existing production workflows, potentially reducing the need for significant capital investment.
In addition to economic benefits, the enzyme systems support more environmentally responsible manufacturing practices by enabling the use of lower-impact solvents, reducing waste generation, and lowering overall process energy requirements. The company's recent advancements are supported by artificial intelligence and computational modeling tools that assist in enzyme analysis and optimization. These tools evaluate biochemical datasets, model structure–function relationships, and assess performance characteristics such as stability, selectivity, and solvent compatibility.
Quantumzyme expects to initiate pilot-scale programs and commercial collaborations with pharmaceutical manufacturing partners beginning in 2026. Multiple validation projects are currently underway to further assess performance across different use cases and production environments. This advancement reinforces Quantumzyme's position in green chemistry and next-generation biocatalysis as the pharmaceutical industry continues to pursue more efficient, resilient, and sustainable manufacturing models.
For more information, visit the Company's website at www.quantumzymecorp.com and its profile at www.otcmarkets.com/stock/QTZM.
